TriSalus Life Sciences (NASDAQ:TLSI) Price Target Raised to $12.00

TriSalus Life Sciences (NASDAQ:TLSI) had its target price boosted by Canaccord Genuity Group from $11.00 to $12.00 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

TLSI has been the topic of several other research reports. Wall Street Zen raised TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of TriSalus Life Sciences in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, TriSalus Life Sciences has a consensus rating of “Hold” and a consensus price target of $11.00.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $7.42 on Wednesday. TriSalus Life Sciences has a 52-week low of $3.42 and a 52-week high of $7.70. The firm has a market capitalization of $370.70 million, a price-to-earnings ratio of -3.67 and a beta of 0.43. The company has a 50 day simple moving average of $5.58 and a 200-day simple moving average of $5.09.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.79). The company had revenue of $11.57 million during the quarter, compared to analyst estimates of $11.76 million. On average, analysts predict that TriSalus Life Sciences will post -1.55 EPS for the current year.

Institutional Investors Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the company. Nantahala Capital Management LLC boosted its stake in TriSalus Life Sciences by 2.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 2,040,245 shares of the company’s stock valued at $9,487,000 after purchasing an additional 40,245 shares during the period. Millennium Management LLC raised its holdings in shares of TriSalus Life Sciences by 17.7% during the 3rd quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock worth $166,000 after buying an additional 5,359 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of TriSalus Life Sciences in the third quarter worth about $343,000. White Pine Capital LLC acquired a new stake in TriSalus Life Sciences in the third quarter valued at approximately $278,000. Finally, Vanguard Group Inc. increased its holdings in TriSalus Life Sciences by 42.4% in the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock worth $5,392,000 after purchasing an additional 345,186 shares in the last quarter. 2.58% of the stock is owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.